Production of Adenovector Based Vaccines

Information

  • Research Project
  • 7028262
  • ApplicationId
    7028262
  • Core Project Number
    R43AI063819
  • Full Project Number
    5R43AI063819-02
  • Serial Number
    63819
  • FOA Number
  • Sub Project Id
  • Project Start Date
    3/15/2005 - 19 years ago
  • Project End Date
    2/28/2009 - 15 years ago
  • Program Officer Name
    KHAMBATY, FARUKH M.
  • Budget Start Date
    3/1/2006 - 18 years ago
  • Budget End Date
    2/28/2009 - 15 years ago
  • Fiscal Year
    2006
  • Support Year
    2
  • Suffix
  • Award Notice Date
    3/29/2006 - 18 years ago
Organizations

Production of Adenovector Based Vaccines

[unreadable] DESCRIPTION (provided by applicant): Adenovirus vectors (AdVectors) designed to express an antigenic gene have shown great promise as vaccines. Although GenVec and other groups have constructed numerous AdVectors expressing a variety of antigens a substantial subset of antigen genes have been found to be inhibitory to AdVector construction and production. In this phase I SBIR proposal we will investigate strategies to circumvent the deleterious effect of inhibitory genes by blocking antigen expression within the AdVector production cell line. These results will guide the building, certification and banking of a commercial cell line during SBIR Phase II. A cell line broadly applicable for production of AdVectors containing inhibitory transgenes is presently not available. During SBIR phase I two different mechanisms of repressing expression, transcriptional and post-transcriptional, will be tested. Aim 1 will optimize a transcriptional repressor, incorporate it into a cell line and demonstrate its functionality on AdVectors with inhibitory genes. Aim 2 will test the hypothesis that a single siRNA can be broadly applied to inhibit transgene expression. It is anticipated that both strategies will be used in the ultimate cell line constructed in phase II. The final GMP manufacturing cell line will speed and facilitate the testing of advector vaccine concepts for many antigens, speed their progress to clinical testing and reduce the cost of goods for future approved vaccine products. [unreadable] [unreadable]

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    R43
  • Administering IC
    AI
  • Application Type
    5
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    298330
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    856
  • Ed Inst. Type
  • Funding ICs
    NIAID:298330\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    GENVEC, INC.
  • Organization Department
  • Organization DUNS
    806729547
  • Organization City
    GAITHERSBURG
  • Organization State
    MD
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    208784021
  • Organization District
    UNITED STATES